Why Journals Resist
Drug Trial Registration

Kermit Cole
0
50

Although publication bias is known to be a serious problem that public drug trial registration is meant to address, only a fraction of journals require registration. A British Medical Journal study published this week finds that editors and publishers may not understand the requirements or benefits of registration, fear that such a policy places them at a competitive disadvantage, and reluctance to reject submissions from developing countries.

Article →

Note from the Editor:
The writers of this article have expressed an interest in responding to comments (and, I assume, questions), and also in writing something for Mad in America if they “get a burst of inspiration/free time.”
Let’s hope we inspire them.

Wager, E., Williams, P.; “Hardly worth the effort”? Medical journals’ policies and their editors’ and publishers’ views on trial registration and publication bias: quantitative and qualitative study. British Medical Journal. Online September 6, 2013. BMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f5248

Previous articlePrescription Drugs in Great Lakes Don’t Dilute as Expected
Next articleTrauma Informed Care
Meets Pharma Informed Care
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected]

LEAVE A REPLY